Clinical Trial Update: Efficacy and Safety of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections [Phase 3]

View source ↗

Summary

Phase 3 trial results evaluate the efficacy and safety of dalbavancin for acute bacterial skin and skin structure infections, including abscesses, cellulitis, w…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Abscess
• Bacterial Skin and Skin Structure Infections
• Cellulitis
• Surgical Site Infection
• Wound Infection

Drugs mentioned

• Dalvance (dalbavancin)

Snippet

Sponsor: Durata Therapeutics Inc., an affiliate of Allergan plc | Conditions: Abscess, Wound Infection | Phase 3 | Status: COMPLETED | Results posted: 2013-12-25